SEARCH

SEARCH BY CITATION

References

  • 1
    Jacoby GA, Sutton L. β-Lactamases and β-lactam resistance in Escherichia coli. Antimicrob Agents Chemother 1985; 28: 703705.
  • 2
    Fernández-Cuenca F, Martínez-Martínez L, Amblar G et al. Susceptibility to amoxicillin–clavulanate in clinical isolates of Escherichia coli resistant to cefoxitin. Clin Microbiol Infect 2006; 12: 197198.
  • 3
    Vila J, Marcos MA, Jiménez de Anta MT. A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus–A. baumannii complex. J Med Microbiol 1996; 44: 482489.
  • 4
    Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, approved standard M7-A6, 6th edn. Wayne, PA: CLSI, 2005.
  • 5
    National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents, approved standard M26-A. Wayne, PA: NCCLS, 1999.
  • 6
    Yong D, Park R, Yum JH et al. Further modification of the Hodge test to screen AmpC beta-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniae. J Microbiol Meth 2002; 51: 407410.
  • 7
    Caroff N, Espaze E, Gautreau D et al. Analysis of the effects of −42 and −32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J Antimicrob Chemother 2000; 45: 783788.
  • 8
    Martínez-Martínez L, Conejo MC, Pascual A et al. Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles. Antimicrob Agents Chemother 2000; 44: 25342536.
  • 9
    Schumaker RC. PKCALC: a basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986; 17: 331348.
  • 10
    Frimodt-Moeller N, Bentzon MW, Thomsen VF. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis 1986; 154: 511517.
  • 11
    Esposito AL, Pennington JE. Effects of aging on antibacterial mechanisms in experimental pneumonia. Am Rev Respir Dis 1983; 128: 662667.
  • 12
    Rodríguez-Hernández MJ, Pachón J, Pichardo C et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 2000; 45: 493501.
  • 13
    Pachón J, Cordero E, Caballero FJ. The importance of other classical pyogenic pathogens (Staphylococcus aureus, gram negative bacteria and others) in community acquired pneumonia. Med Clin (Barc) 1998; 110: 6570.
  • 14
    American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388416.
  • 15
    Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 110.